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Abstract
Objectives: The aim of this study was to assess oncological outcomes in patients treated with pan-
creaticoduodenectomy for advanced pancreatic head adenocarcinoma after preoperative chemoradio-
therapy and to compare these with outcomes in patients treated with surgery alone.
Methods: From 2004 to 2009, patients treated with pancreaticoduodenectomy for pancreatic head
adenocarcinoma were included in a retrospective comparative study. Patients with locally advanced
adenocarcinoma were treated with preoperative chemoradiotherapy (CRT group) and were compared
with those treated with surgery alone (SURG group).
Results: A total of 111 patients were included; these comprised 72 patients in the SURG group and 39
patients in the CRT group. The median follow-up was 21 months. Patients in the CRT group presented
with a more advanced tumoral status. Microscopic resection rates were similar in both groups, but nodal
status and vascular or lymphatic emboli were lower in the CRT group. At 3 years, the SURG and CRT
groups exhibited similar overall (36% and 51%, respectively) and disease-free (35% and 37%, respec-
tively) survival (P = 0.10).
Conclusions: In patients with advanced pancreatic head adenocarcinoma, a good response after
preoperative chemoradiotherapy results in a survival rate similar to that in patients treated with surgery
alone in whom the initial prognosis is better.
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Introduction
Approximately 10 new cases of pancreatic cancer are diagnosed
per 100 000 person-years in Western countries.1,2 Surgery remains
the standard curative therapy for resectable pancreatic cancer,3 but
only 10–15% of patients presenting with pancreatic adenocarci-
noma are able to undergo a potentially curative resection. As a
result of locally advanced pancreatic adenocarcinoma (LAPA) or
distant metastases, the remaining patients are not considered as
candidates for resection. The definition of LAPA, comprising both
borderline and unresectable tumour, is based on the relationship
between the tumour and the coeliac axis (CA) or the superior
mesenteric artery (SMA) and is identified using computed tom-
ography (CT). The disease is considered unresectable when CT
images reveal arterial encasement of either the CA or SMA, or
portal vein thrombosis. Patients diagnosed with non-metastatic
LAPA, however, are likely to undergo chemoradiotherapy (CRT).4
Downstaging after CRT allows surgical resection in 20% of
cases.5–7 Patients with LAPA who underwent pancreaticoduo-
denectomy (PD) after CRT have been shown to enjoy survival
rates that are twice as high as those in patients treated with CRT
alone.8
The aim of this study was to determine the impact of treatment
with CRT prior to PD in patients initially diagnosed with LAPA.
Oncological outcomes in patients who demonstrated a good
response to preoperative CRT and were subsequently treated with
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PD for LAPA were compared with outcomes in patients treated
with surgery alone.
Materials and methods
Population
From 2004 to 2009, patients treated with PD for adenocarcinoma
of the pancreatic head were included in a retrospective compara-
tive study. Patients with endocrine tumours or ampullary, bile
duct or duodenal carcinoma were excluded. All patients under-
went thin-section, contrast-enhanced dynamic CT. Patients with
distant metastases were excluded. Tumours were considered
resectable if there were no distant metastases and no evidence of
superior mesenteric vein (SMV) or portal vein abutment, distor-
tion, tumour thrombus or venous encasement with clear fat
planes around the CA, hepatic artery and SMA. Tumours were
considered borderline resectable in the presence of venous
involvement of the SMV or portal vein demonstrating tumour
abutment with impingement and narrowing of the lumen, encase-
ment of the SMV or portal vein, but without encasement of the
nearby arteries, or abutment of the hepatic artery, without exten-
sion to the CA, or abutment of the SMA of >180 ° of the circum-
ference of the vessel wall.9 Tumours that showed SMA encasement
of >180 °, any coeliac abutment, unreconstructible SMV or portal
vein occlusion or aortic invasion or encasement were considered
unresectable. Patients diagnosed with LAPA (borderline or unre-
sectable tumours) were treated with preoperative CRT (CRT
group) and were compared with patients treated with surgery
alone (SURG group). These patients underwent a pancreatic
biopsy to confirm diagnosis and biliary drainage was assessed by
endoscopy or surgery in patients with obstructive jaundice. End-
points included both global and disease-free survival.
Preoperative radiotherapy
In the process of treatment planning, a CT scan was required to
define target volumes. The following volumes were based on defi-
nitions described by the International Commission on Radiation
Units and Measurements.10 Gross tumour volume (GTV) was
determined during the planning of treatment using slice-by-slice
CT scans; the clinical target volume (CTV) was defined as the
GTV plus the regional lymph nodes, and the planning target
volume 1 (PTV1) included the CTV plus safety margins of 10 mm
in all transverse directions and 20 mm craniocaudally to allow for
breathing. Following treatment with 45 Gy, the reduced PTV
(PTV2) was limited to the GTV and the area between the coeliac
trunk and the upper mesenteric artery plus a safety margin of
10 mm in all transverse directions. The prescribed total dose at the
reference point (isocentre) of PTV1 was 45 Gy in 25 fractions of
1.8 Gy administered five times per week. During the last segment
of treatment, patients received a boost of 14.4 Gy in eight fractions
of 1.8 Gy per day, restricted to the initial tumour volume and the
coeliac area (PTV2).
Preoperative chemotherapy
During preoperative irradiation, patients received concomi-
tant chemotherapy comprising various fluorouracil-based
protocols.11,12 Fluorouracil-based chemotherapy included a 5-
fluorouracil (F-FU)–cisplatin protocol (5-FU, 300 mg/m2/day
administered as a continuous infusion on days 1–5 in each week;
cisplatin, 20 mg/m2/day administered on days 1–5 in weeks 1 and
5 of a 6-week period) and an LV5FU2–cisplatin protocol (folinic
acid, 400 mg/m2 on day 1; cisplatin, 50 mg/m2 on day 1; 5-FU,
400 mg/m2 as a bolus infusion followed by 1200 mg/m2 as a con-
tinuous infusion on day 1 and 1200 mg/m2 as a continuous infu-
sion on day 2 twice per month).
Patients were treated with chemotherapy alone prior to CRT
using protocols based on gemcitabine and cisplatin. Briefly,
chemotherapy included gemcitabine alone (1000 mg/m2 once per
week for 2 months during the first cycle and for 1 month during
additional cycles) and the GEMCIS protocol (gemcitabine,
1000 mg/m2 and cisplatin, 25 mg/m2 administered on days 1, 8, 15
and 28).
Since 2007, patients who might benefit from CRT have been
selected using the therapeutic strategy described by the Groupe
Coopérateur Multidisciplinaire en Oncologie [GERCOR (Group
for Multidisciplinary Cooperation in Oncology)],13 which initially
consisted of chemotherapy for 3 months. Patients underwent
CRT if the disease did not progress during3 months of chemo-
therapy. This chemotherapy protocol included a combination of
gemcitabine and oxaliplatin, GEMOX (gemcitabine, 1000 mg/m2
on day 1, oxaliplatin, 100 mg/m2 on day 2, twice per month).
Response assessment
The therapeutic response was evaluated according to the RECIST
(response evaluation criteria in solid tumours) system,14 using a
CT scan performed 4 weeks following the end of treatment. Sur-
gical exploration was scheduled in patients in whom either down-
sizing of the tumour or a decrease in the carbohydrate antigen
19-9 (CA 19-9) tumour marker was seen.
Surgical procedure
Surgical exploration was performed 5–6 weeks following CRT
completion. The first step in this procedure involved complete
exploration of the abdominal cavity to rule out a contraindication
for resection (i.e. hepatic or peritoneal metastases). Pancreati-
coduodenectomy was performed in accordance with the Whipple
procedure. In all cases, the first step consisted of dissection of the
SMA. This surgical approach on the SMA was performed using
the Kocher manoeuvre.15 To harvest biopsies of tissue in contact
with arterial adventitia along the entire length and circumference
of the initial LAPA required the artery to be separated from the
encasement. During this process, the origin of the SMA may have
been exposed and dissected. If all biopsies were negative, then a
Whipple procedure was performed; however, if all biopsies were
not negative, a palliative bypass was conducted. An en bloc PD
with segmental portal vein resection (PVR) was performed in
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some patients. Portomesenteric reconstruction was performed by
direct anastomosis without a prosthetic graft procedure. Speci-
mens were stained by the surgeon on the portal vein (blue), artery
(red) and retroportal area (yellow).
Postoperative morbidity was considered according to the clas-
sification system of Dindo et al.16 and pancreatic fistulae (PF) were
defined as amylase-rich fluid, of more than three times serum
concentration, collected from the drain placed intraoperatively in
the abdomen from day 3 in accordance with criteria defined by the
International Study Group on Pancreatic Fistula (ISGPF).17
Statistical analysis
Endpoints consisted of overall and disease-free survival. Variables
analysed included age, sex, body mass index (BMI), American
Society of Anesthesiologists (ASA) score, tumour and nodal status
(before and after preoperative CRT), artery or vein involvement,
and microscopic outcomes (e.g. type of resection, vascular or
lymphatic emboli, and perineural invasion).
Survival was defined as the length of time from the beginning of
treatment (surgery or CRT) until death. Global and disease-free
survival were assessed using the Kaplan–Meier method and were
compared using the log-rank test.
Differences between groups were determined by chi-squared or
Fisher’s exact tests as appropriate. All variables associated with
overall or disease-free survival for which P-values of 0.10 were
found in univariate analysis were considered for multivariable
analysis using a logistic regression model.
Results
Population and tumour characteristics
A total of 111 patients were included in this study. Outcome data
for 72 patients treated with surgery alone were compared with
equivalent data for 39 patients treated with preoperative CRT. The
median follow-up was 21 months. Patients treated with preopera-
tive CRT were younger than those treated initially with surgery.
Preoperative tumour and nodal statuses were more advanced in
the CRT group, which showed a higher rate of artery or vein
involvement. One patient with T1 tumour status, who presented
preoperatively with a positive nodal status, underwent preopera-
tive CRT. Clinical and tumour characteristics and details of preop-
erative chemotherapy are reported in Tables 1 and 2. A total of 10
patients underwent chemotherapy for 3 months followed by CRT
prior to surgery.
Operative procedure characteristics
During the Whipple procedure, the rate of vein resection was
higher in the CRT group (Table 3). Only one artery resection was
conducted in the CRT group and none were conducted in the
SURG group. Pancreatic tissue was considered fibrous in 41% and
73% of patients in the SURG and preoperative CRT groups,
respectively. This difference was not significant.
Postoperative complications
No difference in surgical morbidity was detected between the two
groups. However, rates of PF were 28% in the SURG group and
13% in the CRT group. In line with the rate of fibrous pancreatic
tissue, this difference in the incidence of PF was not significant
(P = 0.07).
Histology
Microscopic analysis of the specimen revealed that the rate of
positive node and vascular or lymphatic emboli was lower in the
CRT group than in the SURG group. Tumours were sterilized in
five patients who received preoperative CRT. Patients in the CRT
group exhibited less perineural invasion, but this difference was
not significant. Rates of microscopic negative-margin resection
were similar in both groups (Table 3).
Overall and disease-free survival
No significant difference was detected between the two groups in
either overall survival or disease-free survival (31% and 19%,
respectively, in the entire cohort). At 3 years, overall survival rates
in the SURG and preoperative CRT groups were 36% and 51%,
respectively (P = 0.096); disease-free survival rates in the SURG
and preoperative CRT groups were 35% and 37%, respectively
(P = 0.249) (Figs 1, 2).
Treatment characteristics (e.g. preoperative radiotherapy and
resection type) and nodal status did not influence overall survival.
By contrast, patient characteristics (e.g. age and ASA score) and
tumour characteristics (e.g. vascular or lymphatic emboli and
tumour status) did influence overall survival. Based on multivari-
ate analysis, independent factors for overall survival were patient
age of >65 years [odds ratio (OR) 1.98, 95% confidence interval
(CI) 1.01–3.90; P = 0.049] and low degree of tumour differentia-
tion (OR 3.09, 95% CI 1.16–8.18; P = 0.024).
The only factors associated with disease-free survival were the
tumour characteristics of low differentiation and vascular or lym-
phatic emboli. Results of the multivariate analysis indicated that
the independent factors associated with disease-free survival were
low degree of tumour differentiation (OR 3.26, 95% CI 1.27–8.41;
P = 0.014) and vascular or lymphatic emboli (OR 2.05, 95% CI
1.13–3.69; P = 0.018).
Discussion
Radical surgery, which achieves tumour-free margins (R0), repre-
sents the only potentially curative option for patients diagnosed
with adenocarcinoma of the pancreatic head.3 Unfortunately,
fewer than 20% of patients with pancreatic adenocarcinoma have
potentially resectable tumours. For patients with unresectable
lesions, the standard of care consists of chemoradiation with con-
current 5-FU.12 This regimen often includes cisplatin6,7,18 or, more
recently, concurrent gemcitabine,19 which may be used in combi-
nation with oxaliplatin.20 A few studies have demonstrated that
CRT will occasionally downstage locally advanced unresectable
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Table 1 Clinical and tumour characteristics in patients with advanced pancreatic head adenocarcinoma (n = 111)
SURG group (n = 72) CRT group (n = 39) P-valueb
n (%) n (%)
Age 0.002
65 years 28 (38.9) 27 (69.2)
>65 years 44 (61.1) 12 (30.8)
Sex 0.059
Male 43 (59.7) 16 (41.0)
Female 29 (40.3) 23 (59.0)
Body mass index, kg/m2a 0.966
23 kg/m2 26 (53.1) 15 (53.6)
>23 kg/m2 23 (46.9) 13 (46.4)
ASA scorea 0.758
1 20 (27.8) 13 (33.3)
2 44 (61.1) 21 (53.8)
3 8 (11.1) 5 (12.8)
Preoperative status
Tumour statusa <0.001
T1 29 (41.4) 1 (2.6)
T2 32 (45.7) 0
T3 9 (12.9) 14 (35.9)
T4 0 24 (61.5)
Nodal status 0.001
N- 61 (88.4) 20 (58.8)
N+ 8 (11.6) 14 (41.2)
Vein involvementa <0.001
Yes 8 (11.6) 24 (64.9)
No 61 (88.4) 13 (35.1)
Artery involvementa <0.001
Yes 0 22 (59.5)
No 69 (100) 15 (40.5)
Postoperative status
Tumour statusa <0.001
T0 0 5 (12.8)
T1 29 (41.4) 3 (7.7)
T2 32 (45.7) 4 (10.3)
T3 9 (12.9) 27 (69.2)
T4 0 0
Resection type 0.240
R0 54 (75.0) 33 (84.6)
R1 18 (25.0) 6 (15.4)
Vascular/lymphatic emboli 0.001
Yes 32 (55.2) 7 (20.0)
No 26 (44.8) 28 (80.0)
Perineural invasiona 0.065
Yes 40 (70.2) 19 (51.4)
No 17 (29.8) 18 (48.6)
Nodal status <0.001
N- 16 (22.2) 23 (59.0)
N+ 56 (77.8) 16 (41.0)
aMissing data.
bP-values in bold are significant at P  0.01.
SURG group, surgery-only group; CRT group, preoperative chemoradiotherapy group; ASA, American Society of Anesthesiologists.
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pancreatic tumours to allow for surgical resection.5–7,21 In agree-
ment with a recent review,22 the present results demonstrate that a
good tumour response to preoperative CRT for adenocarcinoma
of the pancreatic head results in better overall survival than
surgery alone in patients who present with a better prognosis
initially. This difference was not significant in the present study,
probably as a result of the small size of the study population. The
retrospective nature of this study, the heterogeneity of treatment
and the small population size resulted in decreased statistical
power for the present analyses. As demonstrated in clinical studies
of CRT, one potential disadvantage of preoperative CRT is that it
is associated with increased perioperative morbidity and mortal-
ity.7,18 However, in the present study, preoperative CRT did not
increase perioperative morbidity, particularly PF, or mortality, as
has been previously reported elsewhere.23
This study emphasizes the impact of downstaging LAPA using
CRT. In this series, a high rate of R0 resection was noted in the
preoperative CRT group (85%). This procedure involved an
extended resection that required portal vein resection and recon-
struction in half of these patients. In series that have included only
patients with primarily unresectable pancreatic cancer, rates of
R0/total resections ranged from 57% to 100%.22 This proportion
is remarkable in comparison with the rate of R0 resection
reported in the present study and is in agreement with rates
recently reported in the literature, which vary from 25% to 84% in
patients with primarily resected pancreatic adenocarcinoma.24–26
Additionally, the rate of positive nodal disease following treatment
was lower in the preoperative CRT group than in the SURG group,
which represents a reversal of the nodal status observed in CT
scans prior to treatment. Survival has been shown to be directly
influenced by nodal status.27–29 In the present study, nodal status
did not affect survival, but the presence of fewer vascular or lym-
phatic emboli influenced disease-free survival. The degree of
tumour differentiation and patient age impacted upon overall
survival.
In the present study, patients diagnosed with LAPA who under-
went PD as a result of downstaging subsequent to CRT demon-
strated overall and disease-free survival comparable with those in
resectable patients treated with surgery alone. The present series
demonstrated a reversal of the expected trend; patients with early-
stage resectable carcinoma survived longer than patients with
more advanced regional disease. These findings are similar to
results reported in other studies.18,23,30 In a previous study, this
group reported that approximately 20% of patients treated with
CRT for LAPA underwent surgical resection.5 Although this subset
of patients was selected among patients who initially presented
with a poor prognosis, the entire group responded positively to
the preoperative treatment. Non-responders, or patients with
metastases, underwent palliative care. In a series of resected, early-
stage pancreatic tumours, approximately 20% of metastases
occurred within 3 months following surgery, resulting in a nega-
tive impact on survival; therefore, the exclusion of these patients
should be considered when interpreting the results.31 The present
authors hypothesize, however, that the downstaging and downsiz-
Table 2 Preoperative chemotherapy in patients with advanced pan-
creatic head adenocarcinoma (n = 39)
Preoperative
chemotherapy = 39)
n %
5-Fluorouracil + cisplatin 3 7.7
LV5FU2 + cisplatin 8 20.5
Gemcitabine 4 10.3
Gemcitabine + cisplatin 14 35.9
Gemcitabine + oxaliplatin 10 25.6
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Figure 1 Kaplan–Meier curves showing overall survival in 111
patients subjected to pancreaticoduodenectomy for advanced pan-
creatic head adenocarcinoma, of whom 39 were treated with preop-
erative chemoradiotherapy (CRT) and 72 were treated with surgery
alone
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Figure 2 Kaplan–Meier curves showing disease-free survival in 111
patients subjected to pancreaticoduodenectomy for advanced pan-
creatic head adenocarcinoma, of whom 39 were treated with preop-
erative chemoradiotherapy (CRT) and 72 were treated with surgery
alone
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ing of the tumour are responsible for this effect on survival, and
the significant reduction of nodal involvement is the most obvious
parameter with which to support this hypothesis. Moreover, only
one in four patients in the CRT group underwent postoperative
chemotherapy, whereas over half of the patients in the SURG
group underwent chemotherapy following surgery. Treatment
with postoperative chemotherapy in patients who have received
preoperative CRT may decrease the distant recurrence rate and
more significantly increase overall and disease-free survival.
Although surgery remains the standard curative therapy for
resectable pancreatic cancer, very similar rates of survival were
observed in the two treatment groups assessed in this study, which
Table 3 Treatment and postoperative course characteristics in patients with advanced pancreatic head adenocarcinoma treated with
pancreaticoduodenectomy (n = 111)
SURG group (n = 72) CRT group (n = 39) P-valueb
n (%) n (%)
Vein resectiona 0.041
Yes 22 (31.4) 20 (51.3)
No 48 (68.6) 19 (48.7)
Artery resection 0.351
Yes 0 1 (2.6)
No 72 (100) 38 (97.4)
Extensive nodal resection (N2) 0.420
Yes 5 (7.0) 1 (2.6)
No 66 (93.0) 38 (97.4)
Pancreatic anastomosis 1.000
Gastric 8 (11.1) 4 (10.3)
Jejunal 64 (88.9) 35 (89.7)
Pancreas appearancea 0.243
Normal 9 (17.0) 3 (9.1)
Soft 15 (28.3) 6 (18.2)
Fibrous 29 (41.4) 24 (72.7)
Pancreatic fistula 0.072
Yes 20 (27.8) 5 (12.8)
No 52 (72.2) 34 (87.2)
Biliary fistula 1.000
Yes 4 (5.6) 2 (5.1)
No 68 (94.4) 37 (94.9)
Gut fistula 1.000
Yes 1 (1.4) 0
No 71 (98.6) 39 (100)
Sepsis/collection 0.117
Yes 16 (22.2) 4 (10.3)
No 56 (77.8) 35 (89.7)
Postoperative haemorrhage 0.418
Yes 6 (8.3) 1 (2.6)
No 66 (91.7) 38 (97.4)
Postoperative treatment <0.001
None 23 (33.3) 26 (74.3)
Chemotherapy 37 (53.6) 9 (25.7)
Radiochemotherapy 9 (13.0) 0
aMissing data.
bP-values in bold are significant at P  0.01.
SURG group, surgery-only group; CRT group, preoperative chemoradiotherapy group.
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is in agreement with previous studies.18,23,30 Although it is impor-
tant to note that the patients who underwent PD after preopera-
tive CRT represented a selected subset of patients, this observation
may suggest a defect in selecting patients who have been treated
with radical surgery alone. Moreover, the survival of patients in
the CRT group was estimated from the beginning of preoperative
treatment, whereas the survival of patients in the SURG group was
estimated from the time of surgery and this difference may have
led to a time-associated bias in the assessment of overall survival.
Additionally, 13–21% of patients in whom preoperative thin-
section, contrast-enhanced dynamic CT indicated resectable
tumour were found to show contraindications for Whipple
surgery during the laparotomy for local progression, carcinoma-
tosis or metastasis.32,33 These patients were not included in the
present study, which leads to another bias in selection. Finally,
Massucco and co-workers demonstrated that primarily resected
patients who were not treated with adjuvant therapy exhibited the
same median survival as unresectable patients treated with CRT
alone.23 Golcher et al. suggested that preoperative CRT may
increase survival in patients with resectable disease.30 Because
distant metastases determine prognosis and develop frequently
as the disease progresses, this strategy may be beneficial to sur-
geons selecting patients for surgery and may help to avoid early
recurrences.
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